Patents by Inventor Marc Martinell Pedemonte

Marc Martinell Pedemonte has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Lysine demethylase inhibitors for myeloproliferative disorders
    Patent number: 9908859
    Abstract: The invention relates to methods and compositions for the treatment or prevention of diseases and disorders associated with myeloproliferative disorders. In particular, the invention relates to an LSD 1 inhibitor for use in treating or preventing Philadelphia chromosome negative myeloproliferative disorders.
    Type: Grant
    Filed: February 20, 2014
    Date of Patent: March 6, 2018
    Assignee: Oryzon Genomics, S.A.
    Inventors: Jonathan Alleman Baker, Julio Castro Palomino, Matthew Colin Thor Fyfe, Tamara Maes, Marc Martinell Pedemonte
  • 2,4-thiazolidinedione derivatives in the treatment of central nervous system disorders
    Patent number: 9782395
    Abstract: The present invention provides 5-(4-(2-(5-(1-hydroxyethyl)pyridine-2-yl)ethoxy) benzyl)thiazolidine-2,4-dione and novel stereoisomers of said compound for use in the treatment of central nervous system (NS) disorders.
    Type: Grant
    Filed: May 5, 2016
    Date of Patent: October 10, 2017
    Assignee: MINORYX THERAPEUTICS S.L.
    Inventors: Ana María García Collazo, David John Augustus Eckland, Maria Pilar Pizcueta Lalanza, Marc Martinell Pedemonte
  • LYSINE DEMETHYLASE INHIBITORS FOR MYELOPROLIFERATIVE OR LYMPHOPROLIFERATIVE DISEASES OR DISORDERS
    Publication number: 20170209432
    Abstract: The present invention relates to methods and compositions for the treatment or prevention of diseases and disorder associated with myeloproliferative and lymphoproliferative disorders. In particular, the invention relates to an LSD1 inhibitor for use in treating or preventing diseases and disorder associated with myeloproliferative and lymphoproliferative disorders.
    Type: Application
    Filed: December 5, 2016
    Publication date: July 27, 2017
    Inventors: Matthew Colin Thor FYFE, Tamara MAES, Marc MARTINELL PEDEMONTE, Inigo TIRAPU FERNANDEZ DE LA CUESTA
  • Arylcyclopropylamine based demethylase inhibitors of LSD1 and their medical use
    Patent number: 9708309
    Abstract: The invention relates to (hetero)aryl cyclopropylamine compounds, including particularly the compounds of formula (I) as described and defined herein, and their use in therapy, including, e.g., in the treatment or prevention of cancer, a neurological disease or condition, or a viral infection. Thus, in one specific aspect the invention relates to formulas (II), (III), (IV), (V), (VI), (VII), (VIII), (IX).
    Type: Grant
    Filed: September 9, 2015
    Date of Patent: July 18, 2017
    Assignee: ORYZON GENOMICS, S.A.
    Inventors: Alberto Ortega Muñoz, Matthew Colin Thor Fyfe, Marc Martinell Pedemonte, Iñigo Tirapu Fernandez De La Cuesta, Maria de los Ángeles Estiarte-Martinez
  • Cyclopropylamine derivatives useful as LSD1 inhibitors
    Patent number: 9676701
    Abstract: The invention relates to cyclopropylamine compounds, in particular the compounds of Formula (I), and their use in therapy, including e.g. in the treatment or prevention of cancer, a neurological disease or condition, or viral infection.
    Type: Grant
    Filed: March 6, 2015
    Date of Patent: June 13, 2017
    Assignee: ORYZON GENOMICS, S.A.
    Inventors: Matthew Colin Thor Fyfe, Alberto Ortega Muñoz, Julio Castro-Palomino Laria, Marc Martinell Pedemonte, Maria de los Angeles Estiarte-Martinez, Nuria Valls Vidal
  • (Hetero)aryl cyclopropylamine compounds as LSD1 inhibitors
    Patent number: 9670136
    Abstract: The invention relates to (hetero)aryl cyclopropylamine compounds, including particularly the compounds of formula (I) as described and defined herein, and their use in therapy, including, e.g., in the treatment or prevention of cancer, a neurological disease or condition, or a viral infection.
    Type: Grant
    Filed: September 1, 2016
    Date of Patent: June 6, 2017
    Assignee: ORYZON GENOMICS S.A.
    Inventors: Alberto Ortega Muñoz, Matthew Colin Thor Fyfe, Marc Martinell Pedemonte, Maria de los Àngeles Estiarte Martinez, Nuria Valls Vidal, Guido Kurz, Julio Cesar Castro Palomino Laria
  • (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS
    Publication number: 20170008844
    Abstract: The invention relates to (hetero)aryl cyclopropylamine compounds, including particularly the compounds of formula I as described and defined herein, and their use in therapy, including, e.g., in the treatment or prevention of cancer, a neurological disease or condition, or a viral infection.
    Type: Application
    Filed: September 21, 2016
    Publication date: January 12, 2017
    Inventors: Alberto ORTEGA MUÑOZ, Matthew Colin Thor FYFE, Marc MARTINELL PEDEMONTE, Maria de los Àngeles ESTIARTE MARTINEZ, Nuria VALLS VIDAL, Guido KURZ, Julio Cesar CASTRO PALOMINO LARIA
  • (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS
    Publication number: 20160368857
    Abstract: The invention relates to (hetero)aryl cyclopropylamine compounds, including particularly the compounds of formula (I) as described and defined herein, and their use in therapy, including, e.g., in the treatment or prevention of cancer, a neurological disease or condition, or a viral infection.
    Type: Application
    Filed: September 1, 2016
    Publication date: December 22, 2016
    Inventors: Alberto ORTEGA MUÑOZ, Matthew Colin Thor FYFE, Marc MARTINELL PEDEMONTE, Maria de los Àngeles ESTIARTE MARTINEZ, Nuria VALLS VIDAL, Guido KURZ, Julio Cesar CASTRO PALOMINO LARIA
  • (Hetero)aryl cyclopropylamine compounds as LSD1 inhibitors
    Patent number: 9487512
    Abstract: The invention relates to (hetero)aryl cyclopropylamine compounds, including particularly the compounds of formula I as described and defined herein, and their use in therapy, including, e.g., in the treatment or prevention of cancer, a neurological disease or condition, or a viral infection.
    Type: Grant
    Filed: October 22, 2012
    Date of Patent: November 8, 2016
    Assignee: Oryzon Genomics S.A.
    Inventors: Alberto Ortega Muñoz, Matthew Colin Thor Fyfe, Marc Martinell Pedemonte, Maria de los Angeles Estiarte Martinez, Nuria Valls Vidal, Guido Kurz, Julio Cesar Castro Palomino Laria
  • (Hetero)aryl cyclopropylamine compounds as LSD1 inhibitors
    Patent number: 9469597
    Abstract: The invention relates to (hetero)aryl cyclopropylamine compounds, including particularly the compounds of formula (I) as described and defined herein, and theft use in therapy, including, e.g., in the treatment or prevention of cancer, a neurological disease or condition, or a viral infection.
    Type: Grant
    Filed: October 22, 2012
    Date of Patent: October 18, 2016
    Assignee: Oryzon Genomics S.A.
    Inventors: Alberto Ortega Muñoz, Matthew Colin Thor Fyfe, Marc Martinell Pedemonte, María de los Ángeles Estiarte Martínez, Nuria Valls Vidal, Guido Kurz, Julio Cesar Castro Palomino Laria
  • 2,4-THIAZOLIDINEDIONE DERIVATIVES IN THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS
    Publication number: 20160235729
    Abstract: The present invention provides 5-(4-(2-(5-(1-hydroxyethyl)pyridine-2-yl)ethoxy) benzyl)thiazolidine-2,4-dione and novel stereoisomers of said compound for use in the treatment of central nervous system (NS) disorders.
    Type: Application
    Filed: May 5, 2016
    Publication date: August 18, 2016
    Applicant: MINORYX THERAPEUTICS S.L.
    Inventors: Ana Maria Garcia Collazo, David John Augustus Eckland, Maria Pilar Pizcueta Lalanza, Marc Martinell Pedemonte
  • DI(HETERO)ARYLAMIDES AND SULFONAMIDES, METHODS FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF
    Publication number: 20160168132
    Abstract: The present invention refers to compounds of formula (I): as well as to a method for their preparation, pharmaceutical compositions comprising the same, and use thereof for the treatment and/or prevention of conditions associated with the alteration of the activity of ?-galactosidase, specially galactosidase beta-1 or GLB1, including GM1 gangliosidoses and Morquio syndrome, type B.
    Type: Application
    Filed: July 30, 2014
    Publication date: June 16, 2016
    Applicant: Minoryx Therapeutics S.L.
    Inventors: Xavier BARRIL ALONSO, Ana Maria GARCÍA COLLAZO, Juan AYMAMI BOFARULL, Marc REVÉS VILAPLANA, Rodolfo LAVILLA GRIFOLS, Marc MARTINELL PEDEMONTE
  • CYCLOPROPYLAMINE DERIVATIVES USEFUL AS LSD1 INHIBITORS
    Publication number: 20160052865
    Abstract: The invention relates to cyclopropylamine compounds, in particular the compounds of Formula (I), and their use in therapy, including e.g. in the treatment or prevention of cancer, a neurological disease or condition, or viral infection.
    Type: Application
    Filed: March 6, 2015
    Publication date: February 25, 2016
    Inventors: Matthew Colin Thor FYFE, Alberto ORTEGA MUÑOZ, Julio CASTRO-PALOMINO LARIA, Marc MARTINELL PEDEMONTE, Maria de los Angeles ESTIARTE-MARTINEZ, Nuria VALLS VIDAL
  • CYCLOPROPYLAMINE INHIBITORS OF OXIDASES
    Publication number: 20160000768
    Abstract: The invention relates to cyclopropylamine compounds, in particular the compounds of Formula (I) as described and defined herein, and their use in therapy, including, e.g., the treatment or prevention of cancer.
    Type: Application
    Filed: May 13, 2015
    Publication date: January 7, 2016
    Inventors: Julio Castro-Palomino Laria, Matthew Colin Thor Fyfe, Marc Martinell Pedemonte, Alberto Ortega Muñoz, Núria Valls Vidal
  • ARYLCYCLOPROPYLAMINE BASED DEMETHYLASE INHIBITORS OF LSD1 AND THEIR MEDICAL USE
    Publication number: 20150376177
    Abstract: The invention relates to (hetero)aryl cyclopropylamine compounds, including particularly the compounds of formula (I) as described and defined herein, and their use in therapy, including, e.g., in the treatment or prevention of cancer, a neurological disease or condition, or a viral infection. Thus, in one specific aspect the invention relates to formulas (II), (III), (IV), (V), (VI), (VII), (VIII), (IX).
    Type: Application
    Filed: September 9, 2015
    Publication date: December 31, 2015
    Inventors: Alberto ORTEGA MUÑOZ, Matthew Colin Thor FYFE, Marc MARTINELL PEDEMONTE, Iñigo TIRAPU FERNANDEZ DE LA CUESTA, Maria de los Ángeles ESTIARTE-MARTINEZ
  • Arylcyclopropylamine based demethylase inhibitors of LSD1 and their medical use
    Patent number: 9181198
    Abstract: The invention relates to (hetero)aryl cyclopropylamine compounds, including particularly the compounds of formula (I) as described and defined herein, and their use in therapy, including, e.g., in the treatment or prevention of cancer, a neurological disease or condition, or a viral infection. Thus, in one specific aspect the invention relates to formulas (II), (III), (IV), (V), (VI), (VII), (VIII), (IX).
    Type: Grant
    Filed: July 27, 2011
    Date of Patent: November 10, 2015
    Assignee: Oryzon Genomics S.A.
    Inventors: Alberto Ortega Muñoz, Matthew Colin Thor Fyfe, Marc Martinell Pedemonte, Iñigo Tirapu Fernandez de la Cuesta, Maria de los Ángeles Estiarte-Martínez
  • LYSINE DEMETHYLASE INHIBITORS FOR MYELOPROLIFERATIVE DISORDERS
    Publication number: 20150232436
    Abstract: The invention relates to methods and compositions for the treatment or prevention of diseases and disorders associated with myeloproliferative disorders. In particular, the invention relates to an LSD 1 inhibitor for use in treating or preventing Philadelphia chromosome negative myeloproliferative disorders.
    Type: Application
    Filed: February 20, 2014
    Publication date: August 20, 2015
    Inventors: Jonathan Alleman Baker, Julio Castro Palomino, Matthew Colin Thor Fyfe, Tamara Maes, Marc Martinell Pedemonte
  • Cyclopropylamine inhibitors of oxidases
    Patent number: 9061966
    Abstract: The invention relates to cyclopropylamine compounds, in particular the compounds of Formula (I) as described and defined herein, and their use in therapy, including, e.g., the treatment or prevention of cancer.
    Type: Grant
    Filed: October 7, 2011
    Date of Patent: June 23, 2015
    Assignee: ORYZON GENOMICS S.A.
    Inventors: Julio Castro-Palomino Laria, Matthew Colin Thor Fyfe, Marc Martinell Pedemonte, Alberto Ortega Muñoz, Núrla Valls Vidal
  • (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS
    Publication number: 20150119396
    Abstract: The invention relates to (hetero)aryl cyclopropylamine compounds, including particularly the compounds of formula (I) as described and defined herein, and theft use in therapy, including, e.g., in the treatment or prevention of cancer, a neurological disease or condition, or a viral infection.
    Type: Application
    Filed: October 22, 2012
    Publication date: April 30, 2015
    Inventors: Alberto Ortega Muñoz, Matthew Colin Thor Fyfe, Marc Martinell Pedemonte, Maria de los Angeles Estiarte Martínez, Nuria Valls Vidal, Guido Kurz, Julio Cesar Castro Palomino Laria
  • Cyclopropylamine derivatives useful as LSD1 inhibitors
    Patent number: 9006449
    Abstract: The invention relates to cyclopropylamine compounds, in particular the compounds of Formula (I), and their use in therapy, including e.g. in the treatment or prevention of cancer, a neurological disease or condition, or viral infection.
    Type: Grant
    Filed: July 27, 2011
    Date of Patent: April 14, 2015
    Assignee: Oryzon Genomics, S.A.
    Inventors: Matthew Colin Thor Fyfe, Alberto Ortega Muñoz, Julio Castro-Palomino Laria, Marc Martinell Pedemonte, Maria de los Ángeles Estiarte-Martinez, Nuria Valls Vidal